Add time:08/07/2019         Source:sciencedirect.com

The rapid discovery of a pharmacological chaperone toward human α-Gal A for the treatment of Fabry disease is described. Two polyhydroxylated pyrrolidines with the (3R,4S,5R) configuration pattern underwent rapid substituent diversity by conjugating the primary aminomethyl moiety of each with a variety of carboxylic acids to generate two libraries (2 × 60 members). Our bioevaluation results showed one member with the (2R,3R,4S,5R) configuration pattern and bearing a 5-cyclohexylpentanoyl group as a substituent moiety possessed sufficient chaperoning capability to rescue α-Gal A activity in the lymphocyte of the N215S Fabry patient-derived cell line and other α-Gal A mutants in COS7 cells.

We also recommend Trading Suppliers and Manufacturers of (3R,4S)-4-aMino-3-hydroxy-2,2-diMethylchroMan-6-carbonitrile (cas 127419-05-0). Pls Click Website Link as below: cas 127419-05-0 suppliers